MedTrace Logo

Treatment Of Radiation Retinopathy Trial

NCT00811200 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2009-07-02

No results posted yet for this study

Summary

The purpose of this study is to demonstrate a statistically significant improvement of visual acuity after treatment using either Lucentis® or Triamcinolone® compared to no treatment, in patients with radiation retinopathy.

Conditions

Interventions

DRUG

ranibizumab

three initial monthly intra vitreal injections with 0.5 mg ranibizumab

DRUG

triamcinolone acetonide

at baseline one intra vitreal injection with 4.0 mg triamcinolone acetonide

OTHER

sham

at baseline one sham-injection

Sponsors & Collaborators

Principal Investigators

  • Martine J Jager, MD, PhD · Leiden University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2012-01-31

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00811200 on ClinicalTrials.gov